The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

分析显示，每8周一次Eylea HD（aflibercept，8毫克）与每4周一次Eylea（aflibercept，2毫克）相较，在治疗视网膜静脉阻塞（RVO）后黄斑水肿患者上达成非劣 ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

目前，针对 nAMD 的主要治疗手段是使用抗血管内皮生长因子 A（VEGFA）药物，像雷珠单抗、贝伐单抗和阿柏西普（aflibercept）等。虽然这些药物能有效抑制新生血管生长，控制病情发展，但治疗过程却让患者苦不堪言。患者需要频繁地进行玻璃体内注射（IVT ...

On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Adverum Biotechnologies (ADVM) announced the initiation of the ARTEMIS Phase 3 study. This pivotal trial is designed to evaluate the efficacy ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS ...